Loading
Microba Life Sciences Limited Stock: price and insider trades · Australia
2 insiders bought €82k of shares over the last 90 days, the latest filed 31 Jul 2026.
Microba Life Sciences Limited: what insiders have been doing
Microba Life Sciences Limited is a listed company. Filings by its managers are published through ASX. 6 insiders have disclosed 6 filings since 18 October 2025.
Not one open-market sale was filed. On the buying side, 2 insiders reported 2 purchases totalling €82k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Those buying include 2 senior executives. One trade stands out by size: a purchase of €76k from Pasquale Rombola, disclosed on 31 July 2026, or 17.3% of market capitalisation.
In all, 1 purchase was made within 30 days of a purchase by another insider of the company. Purchases made close together by different insiders form what is called a cluster. The last insider purchase was made public on 31 July 2026, 78 days ago.
Compared with its exchange (2,222 companies, median 3 filings), a count of 6 filings is above the norm. Our records for Microba Life Sciences Limited go back to 2026, with 2 purchases and no sales on the open market in total.
This summary is built from ASX disclosures alone and does not predict where the share price will go.
Insider Decl.
6
Thresholds
n/a
Buy Volume
€82,363
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleIan Frazer1 buy
Pasquale Rombola1 buy
Since the insiders bought
- +0.0%Entry A$0.00 · Close at T+30 A$0.00
- +0.0%Entry A$0.00 · Close at T+30 A$0.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,194 of 24,148 companies
14.2
score / 100
Value4
Quality24
FCF yld-52%
Earn yld-52%
EV/EBITDA·
ROE-73%
Gross mgn47%
Net mgn-95%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended June 2025 · cache
A$0.04
Analyst consensus
1 analysts1.00/5
A$0.12Target A$0.12(+188%)A$0.12
Income statement
RevenueA$15.7M
Gross profitA$7.4M47% margin
EBITDA-A$10.5M-67% margin
Net income-A$14.9M-140.4% margin
Valuation
PER (forward)-17.3x
P/Book1.2x
Beta2.10
Balance sheet & cash
Market capA$28.7M
Total debtA$3.2M
Free Cash Flow-A$14.9M
Debt / Equity17%
Profitability & ownership
ROE-72.9%
ROA-29.1%
% insiders38.3%
% institutions25.0%
Last declaration on 30 September 2026
Declarations6 total
ShareASXASX:2924-03142507-2A1700763
1 shares@ A$0.0517.34% mcap100.0% of flowShareASXASX:2924-03116736-2A1686997
Canonical exit: 27 Oct 2026 (T+90)
1 shares@ A$0.051.39% mcap100.0% of flowShareASXASX:2924-03116734-2A1686996
Canonical exit: 27 Oct 2026 (T+90)
ShareASXISIN AU0000209868ASX:2924-03110955-2A1684411
ShareASXASX:2924-03102983-2A1678800
ShareASXASX:2924-03102080-2A1678309
6 of 6 declarations
About Microba Life Sciences Limited
Microba Life Sciences Limited is a company focused on developing health solutions based on the microbiome. It is listed on the Australian Securities Exchange (XASX).
